AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23785451 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive injection risk intervention
Number of subjects: 584
Study 23785451 — intervention group
Group type: COMPARATOR
Intervention: Didactic injection risk intervention
Number of subjects: 584
Study 23785451 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions in Tijuana
Number of subjects: 584
Study 23785451 — intervention group
Group type: EXPERIMENTAL
Intervention: Access to syringes and condoms in Tijuana
Number of subjects: 584
Study 23785451 — intervention group
Group type: EXPERIMENTAL
Intervention: Access to syringes and condoms in Juarez
Number of subjects: 584
Study 22864014 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation-based training using simulated patients and simulated gynecologic models
Number of subjects: 56
Study 22864014 — intervention group
Group type: COMPARATOR
Intervention: Traditional training
Number of subjects: 56
Study 19864187 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation intention intervention (self‐administered questionnaire)
Number of subjects: 81
Study 19864187 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 81
Study 17285406 — intervention group
Group type: EXPERIMENTAL
Intervention: Quazepam 15 mg, 30 mg, or 45 mg
Number of subjects: 200
Study 17285406 — intervention group
Group type: EXPERIMENTAL
Intervention: Brotizolam 0.25 mg
Number of subjects: 200
Study 17285406 — intervention group
Group type: COMPARATOR
Intervention: Control group (no drugs)
Number of subjects: 200
Study 15369509 — intervention group
Group type: EXPERIMENTAL
Intervention: RS-arm (two NRTIs + ritonavir + saquinavir)
Number of subjects: 293
Study 15369509 — intervention group
Group type: EXPERIMENTAL
Intervention: NN-arm (two NRTIs + nevirapine + nelfinavir)
Number of subjects: 293
Study 15369509 — intervention group
Group type: EXPERIMENTAL
Intervention: ASD-arm (abacavir + stavudine + didanosine)
Number of subjects: 293
Study 15369509 — intervention group
Group type: COMPARATOR
Intervention: Treatment interruption or poor adherence
Number of subjects: 293
Study 11316407 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic appendicectomy
Number of subjects: 500
Study 11316407 — intervention group
Group type: EXPERIMENTAL
Intervention: Converted to open appendicectomy
Number of subjects: 500
Study 11316407 — intervention group
Group type: COMPARATOR
Intervention: Open appendicectomy
Number of subjects: 500
Study 9532621 — intervention group
Group type: EXPERIMENTAL
Intervention: Correct KR (Knowledge of Results)
Number of subjects: 40
Study 9532621 — intervention group
Group type: EXPERIMENTAL
Intervention: Erroneous (+100 ms) KR
Number of subjects: 40
Study 9532621 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 trials of correct KR followed by 50 trials of erroneous KR
Number of subjects: 40
Study 9532621 — intervention group
Group type: COMPARATOR
Intervention: No KR (Knowledge of Results)
Number of subjects: 40
Study 7975772 — intervention group
Group type: EXPERIMENTAL
Intervention: Colloidal bismuth subcitrate (CBS)
Number of subjects: 5
Study 7975772 — intervention group
Group type: EXPERIMENTAL
Intervention: Basic bismuth salicylate (BSS)
Number of subjects: 5
Study 7975772 — intervention group
Group type: EXPERIMENTAL
Intervention: Basic bismuth gallate (BSG)
Number of subjects: 5
Study 7975772 — intervention group
Group type: EXPERIMENTAL
Intervention: Basic bismuth carbonate (BSC)
Number of subjects: 5
Study 7975772 — intervention group
Group type: EXPERIMENTAL
Intervention: Bismuth aluminate (BA)
Number of subjects: 5
Study 7975772 — intervention group
Group type: EXPERIMENTAL
Intervention: Basic bismuth nitrate (BSN)
Number of subjects: 5
Study 7975772 — intervention group
Group type: EXPERIMENTAL
Intervention: Basic bismuth nitrate (BSN1480)
Number of subjects: 5
Study 3393494 — intervention group
Group type: EXPERIMENTAL
Intervention: Orchiectomy
Number of subjects: 123
Study 3393494 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen therapy
Number of subjects: 123
Study 30689617 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral intervention
Number of subjects: 10
Study 30689617 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral intervention
Number of subjects: 10
Study 30689617 — intervention group
Group type: COMPARATOR
Intervention: Control (CODS test practice)
Number of subjects: 10
Study 28712129 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri DSM 17938
Number of subjects: 54
Study 28712129 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 25986647 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine maintenance treatment (BMT) with 12-step meeting attendance
Number of subjects: 300
Study 23754097 — intervention group
Group type: EXPERIMENTAL
Intervention: Low Intensity (LO) interval training (60-80% W max)
Number of subjects: 20
Study 23754097 — intervention group
Group type: EXPERIMENTAL
Intervention: High Intensity (HI) interval training (80-90% W max)
Number of subjects: 20
Study 23754097 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 20
Study 21524003 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive programme for gingivitis prevention in children with fixed orthodontic appliances
Number of subjects: 80
Study 21524003 — intervention group
Group type: COMPARATOR
Intervention: Control group (no preventive programme)
Number of subjects: 80
Study 20102058 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartane (AT II blocker)
Number of subjects: 69
Study 20102058 — intervention group
Group type: EXPERIMENTAL
Intervention: Niphedipine (calcium channel blocker)
Number of subjects: 69
Study 20102058 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 69
Study 20102058 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison between valsartane and niphedipine
Number of subjects: 69
Study 16769613 — intervention group
Group type: EXPERIMENTAL
Intervention: Astemizole
Number of subjects: 63
Study 16769613 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 14982362 — intervention group
Group type: EXPERIMENTAL
Intervention: Mini-implants (both miniplates and freestanding miniscrews)
Number of subjects: 44
Study 14982362 — intervention group
Group type: EXPERIMENTAL
Intervention: Miniplates
Number of subjects: 44
Study 14982362 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior mandible location
Number of subjects: 44
Study 14982362 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonkeratinized mucosa surrounding implants
Number of subjects: 44
Study 11352886 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine
Number of subjects: 42
Study 11352886 — intervention group
Group type: EXPERIMENTAL
Intervention: GSNO
Number of subjects: 42
Study 11352886 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 9284739 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg/day alendronate (A5)
Number of subjects: 74
Study 9284739 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg/day alendronate (A10)
Number of subjects: 74
Study 9284739 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclical etidronate (CE)
Number of subjects: 74
Study 9284739 — intervention group
Group type: COMPARATOR
Intervention: Calcium carbonate (500 mg/day)
Number of subjects: 74
Study 8406294 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem 10 mg
Number of subjects: 10
Study 8406294 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 3942084 — intervention group
Group type: EXPERIMENTAL
Intervention: Riboflavin supplementation (0.3 mg/day)
Number of subjects: 39
Study 3942084 — intervention group
Group type: COMPARATOR
Intervention: No riboflavin supplementation
Number of subjects: 39
Study 3942084 — intervention group
Group type: EXPERIMENTAL
Intervention: Human milk samples
Number of subjects: 39
Study 30817388 — intervention group
Group type: EXPERIMENTAL
Intervention: Tight glucose control with a protocol including frequent, accurate glucose measurements and avoiding large glucose fluctuations
Number of subjects: 0
Study 30817388 — intervention group
Group type: EXPERIMENTAL
Intervention: Tight glucose control
Number of subjects: 0
Study 29314218 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive rehabilitation
Number of subjects: 29
Study 26186951 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of solifenacin 5 mg and trospium 5 mg with tamsulosin 0.4 mg for 2 months
Number of subjects: 338
Study 26186951 — intervention group
Group type: COMPARATOR
Intervention: Tamsulosin 0.4 mg only
Number of subjects: 338
Study 25457927 — intervention group
Group type: EXPERIMENTAL
Intervention: Youth Readiness Intervention (YRI)
Number of subjects: 436
Study 25457927 — intervention group
Group type: COMPARATOR
Intervention: Education subsidy
Number of subjects: 436
Study 22192849 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid, aluminum-adjuvanted V710 (30 μg)
Number of subjects: 115
Study 22192849 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid, non-adjuvanted V710 (30 μg)
Number of subjects: 115
Study 22192849 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-adjuvanted lyophilized V710 (60 μg)
Number of subjects: 115
Study 22192849 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 115
Study 20140620 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous Redon drain
Number of subjects: 200
Study 20140620 — intervention group
Group type: COMPARATOR
Intervention: Control group without a drain
Number of subjects: 200
Study 18049940 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy supplementation for 2 months
Number of subjects: 40
Study 18049940 — intervention group
Group type: COMPARATOR
Intervention: Equol-producing women
Number of subjects: 40
Study 16280425 — intervention group
Group type: COMPARATOR
Intervention: Step I diet (30% fat with 9% SFAs)
Number of subjects: 86
Study 16280425 — intervention group
Group type: COMPARATOR
Intervention: Step II diet (25% fat with 6% SFAs)
Number of subjects: 86
Study 16280425 — intervention group
Group type: EXPERIMENTAL
Intervention: AAD (38% fat and 14% SFAs)
Number of subjects: 86
Study 12064499 — intervention group
Group type: EXPERIMENTAL
Intervention: Adhesive resin system (Scotchbond MultiPurpose)
Number of subjects: 48
Study 12064499 — intervention group
Group type: COMPARATOR
Intervention: Calcium hydroxide liner (Dycal)
Number of subjects: 48
Study 9477005 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (6.1 mg)
Number of subjects: 40
Study 9477005 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil (benzodiazepine antagonist)
Number of subjects: 40
Study 9477005 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 40
Study 8688987 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorphenamine (CPA) regular release tablet (Histop) 4 mg
Number of subjects: 13
Study 8688987 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation (Piriton) 4 mg
Number of subjects: 13
Study 2203322 — intervention group
Group type: EXPERIMENTAL
Intervention: Psyllium (5.1 g, twice daily for 16 weeks)
Number of subjects: 0
Study 2203322 — intervention group
Group type: COMPARATOR
Intervention: Placebo (cellulose, twice daily for 16 weeks)
Number of subjects: 0
Study 2203322 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Psyllium and Placebo)
Number of subjects: 0
Study 27948 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunitrazepam 4 mg
Number of subjects: 41
Study 27948 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrazepam 10 mg
Number of subjects: 41
Study 27948 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunitrazepam 2 mg
Number of subjects: 41
Study 27948 — intervention group
Group type: COMPARATOR
Intervention: Flurazepam 30 mg
Number of subjects: 41
Study 30662336 — intervention group
Group type: EXPERIMENTAL
Intervention: Naturalistic light (IU)
Number of subjects: 43
Study 30662336 — intervention group
Group type: COMPARATOR
Intervention: Standard indoor lighting (CU)
Number of subjects: 43
Study 30662336 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (IU and CU)
Number of subjects: 43
Study 28314319 — intervention group
Group type: EXPERIMENTAL
Intervention: Genexol-PM (100 mg/m2) and gemcitabine (1,000 mg/m2)
Number of subjects: 39
Study 25975045 — intervention group
Group type: EXPERIMENTAL
Intervention: Acu‐TENS
Number of subjects: 90
Study 25975045 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Number of subjects: 90
Study 25975045 — intervention group
Group type: COMPARATOR
Intervention: Control (sham electrical stimulation)
Number of subjects: 90
Study 23289920 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose nitazoxanide (1,000 mg)
Number of subjects: 0
Study 23289920 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose albendazole (400 mg)
Number of subjects: 0
Study 23289920 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitazoxanide-albendazole combination (1,000 mg-400 mg)
Number of subjects: 0
Study 23289920 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 20358359 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse case-manager
Number of subjects: 46
Study 20358359 — intervention group
Group type: COMPARATOR
Intervention: Multifaceted intervention
Number of subjects: 46
Study 19155032 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation
Number of subjects: 1085
Study 19155032 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood draw visits (6 weeks and 6 months)
Number of subjects: 1085
Study 19155032 — intervention group
Group type: EXPERIMENTAL
Intervention: Community engagement strategies (monitoring losses, allowing mothers to witness blood draw, community meetings)
Number of subjects: 1085
Study 16442641 — intervention group
Group type: EXPERIMENTAL
Intervention: Updating condition (visual stimulus shown before saccade)
Number of subjects: 12
Study 16442641 — intervention group
Group type: COMPARATOR
Intervention: Control condition (no visual stimulation before saccade)
Number of subjects: 12
Study 15036822 — intervention group
Group type: EXPERIMENTAL
Intervention: 70% high carbohydrate/15% low fat diet (hc)
Number of subjects: 53
Study 15036822 — intervention group
Group type: COMPARATOR
Intervention: 55% standard carbohydrate/30% fat diet (sc)
Number of subjects: 53
Study 11754630 — intervention group
Group type: EXPERIMENTAL
Intervention: Typherix
Number of subjects: 400
Study 11754630 — intervention group
Group type: COMPARATOR
Intervention: Typhim Vi
Number of subjects: 400
Study 11754630 — intervention group
Group type: EXPERIMENTAL
Intervention: Typherix (12 months)
Number of subjects: 400
Study 11754630 — intervention group
Group type: COMPARATOR
Intervention: Typhim Vi (12 months)
Number of subjects: 400
Study 11754630 — intervention group
Group type: EXPERIMENTAL
Intervention: Typherix (24 months)
Number of subjects: 400
Study 11754630 — intervention group
Group type: COMPARATOR
Intervention: Typhim Vi (24 months)
Number of subjects: 400
Study 11754630 — intervention group
Group type: EXPERIMENTAL
Intervention: Typherix and Typhim Vi
Number of subjects: 400
Study 9001137 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral creatine supplementation
Number of subjects: 0
Study 9001137 — intervention group
Group type: EXPERIMENTAL
Intervention: Measurements at the magic angle
Number of subjects: 0
Study 9001137 — intervention group
Group type: EXPERIMENTAL
Intervention: Numerical spectral simulations
Number of subjects: 0
Study 8426327 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine
Number of subjects: 151
Study 8426327 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75% bupivacaine
Number of subjects: 151
Study 8426327 — intervention group
Group type: EXPERIMENTAL
Intervention: Lignocaine/bupivacaine mixture
Number of subjects: 151
Study 3303981 — intervention group
Group type: EXPERIMENTAL
Intervention: Hinged cast
Number of subjects: 113
Study 3303981 — intervention group
Group type: COMPARATOR
Intervention: Long leg cast
Number of subjects: 113
Study 30427265 — intervention group
Group type: EXPERIMENTAL
Intervention: Light restriction condition (amber-lens glasses)
Number of subjects: 15
Study 30427265 — intervention group
Group type: COMPARATOR
Intervention: No-light restriction condition (transparent glasses)
Number of subjects: 15
Study 28981811 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivation at 6 months
Number of subjects: 404
Study 28981811 — intervention group
Group type: EXPERIMENTAL
Intervention: Social functioning at 6 months
Number of subjects: 404
Study 28981811 — intervention group
Group type: EXPERIMENTAL
Intervention: Work and school participation at 6 months
Number of subjects: 404
Study 27670928 — intervention group
Group type: EXPERIMENTAL
Intervention: Bonfils™ rigid fibreoptic scope
Number of subjects: 200
Study 27670928 — intervention group
Group type: EXPERIMENTAL
Intervention: SensaScope™ rigid fibreoptic scope
Number of subjects: 200
Study 24898019 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized decision support system (CDSS) used in 59% of cases (182/307)
Number of subjects: 912
Study 24898019 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized decision support system (CDSS)
Number of subjects: 912
Study 23253827 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (n = 141)
Number of subjects: 649
Study 23253827 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 136)
Number of subjects: 649
Study 23253827 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (n = 277)
Number of subjects: 649
Study 19822704 — intervention group
Group type: COMPARATOR
Intervention: Urtoxazumab (0.1 to 3.0 mg/kg in healthy adults; 1.0 and 3.0 mg/kg in pediatric patients)
Number of subjects: 0
Study 19091934 — intervention group
Group type: EXPERIMENTAL
Intervention: Arabic version of Diabetes-39 (D-39)
Number of subjects: 368
Study 15155585 — intervention group
Group type: EXPERIMENTAL
Intervention: C + B pamphlet
Number of subjects: 2700
Study 15155585 — intervention group
Group type: EXPERIMENTAL
Intervention: C + B + M pamphlet
Number of subjects: 2700
Study 15155585 — intervention group
Group type: COMPARATOR
Intervention: C pamphlet
Number of subjects: 2700
Study 11377600 — intervention group
Group type: EXPERIMENTAL
Intervention: Class-I below-knee graduated elastic compression stockings
Number of subjects: 231
Study 11377600 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 231
Study 9203805 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled beclomethasone dipropionate (BDP), 500 micrograms b.i.d.
Number of subjects: 20
Study 9203805 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo, two puffs b.i.d.
Number of subjects: 20
Study 7955800 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenytoin (200 mg orally every 8 hours for 11 doses, then 100 mg for 5 doses)
Number of subjects: 12
Study 7955800 — intervention group
Group type: COMPARATOR
Intervention: Tirilazad mesylate (1.5 mg/kg as 10-minute intravenous infusions every 6 hours for 21 doses)
Number of subjects: 12
Study 3118401 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA, 750 mg)
Number of subjects: 9
Study 3118401 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium-ASA combination (ASA 750 mg, trilithium citrate 126 mg, quinine-2 HCl 4.5 mg)
Number of subjects: 9
Study 3118401 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 29701669 — intervention group
Group type: EXPERIMENTAL
Intervention: Spot urine measurement of DHEAS/serotonin ratio
Number of subjects: 47
Study 29701669 — intervention group
Group type: EXPERIMENTAL
Intervention: Spot urine measurement of serotonin/dopamine ratio
Number of subjects: 47
Study 29701669 — intervention group
Group type: EXPERIMENTAL
Intervention: Spot urine serotonin/dopamine ratio cut-off of >667.38
Number of subjects: 47
Study 26044403 — intervention group
Group type: EXPERIMENTAL
Intervention: docetaxel/cisplatin/5-fluorouracil regimen plus weekly cetuximab
Number of subjects: 1
Study 26044403 — intervention group
Group type: COMPARATOR
Intervention: platinum/5-fluorouracil/cetuximab
Number of subjects: 1
Study 24035670 — intervention group
Group type: EXPERIMENTAL
Intervention: Nature-based sound therapy
Number of subjects: 120
Study 24035670 — intervention group
Group type: COMPARATOR
Intervention: Control group (headphones with no sound)
Number of subjects: 120
Study 22113360 — intervention group
Group type: EXPERIMENTAL
Intervention: 17-α-hydroxyprogesterone caproate (17HPC)
Number of subjects: 16
Study 22113360 — intervention group
Group type: COMPARATOR
Intervention: Corticosteroid (CS)
Number of subjects: 16
Study 20001563 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg 17beta‐estradiol + 0.25 mg norethisterone acetate
Number of subjects: 158
Study 20001563 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg 17beta‐estradiol + 0.1 mg norethisterone acetate
Number of subjects: 158
Study 20001563 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 158
Study 18375890 — intervention group
Group type: EXPERIMENTAL
Intervention: Darbepoetin alpha 500 microg with IV iron
Number of subjects: 396
Study 18375890 — intervention group
Group type: COMPARATOR
Intervention: Darbepoetin alpha 500 microg without IV iron (standard practice)
Number of subjects: 396
Study 16332938 — intervention group
Group type: EXPERIMENTAL
Intervention: GHTe (rhGH and Te)
Number of subjects: 80
Study 16332938 — intervention group
Group type: EXPERIMENTAL
Intervention: GH (recombinant human GH)
Number of subjects: 80
Study 16332938 — intervention group
Group type: EXPERIMENTAL
Intervention: Te (testosterone)
Number of subjects: 80
Study 16332938 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 12730816 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefuroxime
Number of subjects: 102
Study 12730816 — intervention group
Group type: COMPARATOR
Intervention: Cefepime
Number of subjects: 102
Study 10803924 — intervention group
Group type: EXPERIMENTAL
Intervention: TOR20 (20 mg daily)
Number of subjects: 260
Study 10803924 — intervention group
Group type: EXPERIMENTAL
Intervention: TOR40 (40 mg daily)
Number of subjects: 260
Study 10803924 — intervention group
Group type: EXPERIMENTAL
Intervention: TOR60 (60 mg daily)
Number of subjects: 260
Study 8615961 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy, Surgery, and Radiotherapy (C/S/XRT)
Number of subjects: 314
Study 8615961 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy and Radiotherapy (C/XRT)
Number of subjects: 314
Study 1432499 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5% phenylephrine and 0.5% tropicamide
Number of subjects: 39
Study 1432499 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% cyclopentolate and 0.5% tropicamide
Number of subjects: 39
Study 1432499 — intervention group
Group type: COMPARATOR
Intervention: NaCl eye drops
Number of subjects: 39